About Moderna, Inc
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., and Recipharm for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Address: 200 Technology Square, Cambridge, MA, United States, 02139
Moderna, Inc News and around…
Latest news about Moderna, Inc (MRNA) common stock and company :
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you already own MRNA stock, it's too early to sell. If you do not yet own it? It's not too late to buy. The post Recent Weakness May Mean Opportunity With Moderna Stock appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar
Thierry Bernard, QIAGEN CEO, joins Yahoo Finance to discuss the future of Covid-19 testing, interest and supply of at-home covid testing, and the diagnostic industry amid the pandemic.
On Tuesday, it became clear that the FDA plans to allow for a “mix and match” approach to vaccine booster shots, ...
Is (MRNA) Outperforming Other Medical Stocks This Year?
There is a lot of uncertainty surrounding this biotech's prospects.
Johnson & Johnson CFO Joseph J. Wolk joins Yahoo Finance Live to discuss Johnson & Johnson’s recent earnings, the effectiveness of its vaccine, and the importance of innovation.
The U.S. death toll from the coronavirus-borne illness COVID-19 rose above 726,000 on Tuesday, as a report said the Food and Drug Administration is moving to allow people get booster shots of vaccines that are different from their primary doses.
The FDA is planning to allow Americans to get a different booster shot of a COVID-19 vaccine than the one initially taken, ...
This vaccine could come from its candidate that prevents a little-known respiratory virus.
The FDA is moving to soon allow people to have a Covid-19 booster shot different from the vaccine they initially received, according to reports.
By Dhirendra Tripathi
At least initially. It could be a different story over the longer term.
Stocks edge higher ahead of earnings; SEC says GameStop surge powered by believers; FDA set to approve "mix & match' COVID boosters; DraftKings faces Entain bid deadline and Rent the Runway seeks $1.3 billion valuation in Nasdaq IPO.
The Food and Drug Administration is moving to soon allow people to receive booster shots that are different from their first COVID-19 vaccine doses, people familiar with the matter said.
The FDA is delaying its decision to authorizeModerna Inc's(NASDAQ: MRNA) COVID-19 vaccine for adolescents to assess ...
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral antivirals
The regulators might be uncertain whether Moderna’s (MRNA) Covid-19 vaccine is suitable for younger people, but an FDA panel was unanimous in agreement when considering the use of its booster shot. The committee voted 19-0 in favor of a Spikevax booster to be administered at least 6 months following completion of the primary vaccines for individuals over 65, for those between ages 18 to 64 who are at risk either for medical reasons or via occupation and for people in long-term care. So, good new
Is Moderna stock a buy as the FDA and CDC prepare to look at booster shot data from Moderna and Johnson & Johnson?
The longtime sideline reporter said ESPN denied her request for accommodation to not receive the vaccine.
Moderna, Inc. (NASDAQ: MRNA) shares have followed a downtrend ever since completing a double top formation in late September. After ...
A Food and Drug Administration advisory committee voted unanimously Friday that allowing adults who were initially vaccinated with the Johnson & Johnson one-dose vaccine against COVID-19 to get a booster is safe and effective, freeing the way for the agency to authorize its use.
The stock is trying to settle above $335.
There's a super-bullish estimate for Moderna's 2022 sales.
The idea is to offer additional flexibility so that Americans in certain situations can receive booster doses of a different vaccine than they received for their initial dose.
The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.
The vaccine maker has a promising pipeline but an expensive valuation.
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market ...
J&J has set a high bar for its rivals.
These two tiny drugmakers could make early shareholders wealthy.
One biotech CEO thinks so.